Ultragenyx Pharmaceutical (NASDAQ:RARE) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $95.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on RARE. JPMorgan Chase & Co. decreased their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Royal Bank of Canada restated an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. TD Cowen upped their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.46.

Ultragenyx Pharmaceutical Stock Up 0.2 %

Ultragenyx Pharmaceutical stock opened at $43.82 on Tuesday. The firm has a fifty day moving average of $48.74 and a 200-day moving average of $49.35. Ultragenyx Pharmaceutical has a 52-week low of $37.02 and a 52-week high of $60.37. The firm has a market capitalization of $4.05 billion, a P/E ratio of -6.77 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same period last year, the company posted ($2.23) earnings per share. The firm’s revenue was up 42.3% compared to the same quarter last year. On average, research analysts expect that Ultragenyx Pharmaceutical will post -6.2 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the sale, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. This trade represents a 0.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Algert Global LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 46.9% in the third quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock valued at $4,105,000 after buying an additional 23,580 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $17,468,000. Bamco Inc. NY bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $2,666,000. Candriam S.C.A. grew its stake in shares of Ultragenyx Pharmaceutical by 33.1% in the 2nd quarter. Candriam S.C.A. now owns 688,942 shares of the biopharmaceutical company’s stock worth $28,314,000 after purchasing an additional 171,345 shares during the last quarter. Finally, Clearline Capital LP bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $1,355,000. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.